Abstract:
:Genetic engineering of T cells for adoptive immunotherapy in cancer patients has shown significant promise. To ensure optimal antitumor activity and safety, the simultaneous expression of multiple genes is frequently required, and short viral-derived 2A sequences are increasingly preferred for this purpose. Concerns exist, however, that these virus-derived sequences may induce unwanted immune responses, and thus diminish persistence of the gene-modified cells after adoptive transfer. Whereas such responses were absent in immunocompromised recipients, potential immunogenicity in immunocompetent individuals remains a concern. We now address whether ex vivo T cell responses can be elicited against the most widely used 2A sequences (2A-Thosea asigna virus (TAV) or 2A-equine rhinitis virus (ERAV), specifically) in immunocompetent individuals. We used a potent ex vivo culture system previously validated to induce T cell responses even against weakly immunogenic antigens. Of the sixteen donors tested, only five released very low levels of interferon-γ in response to 2A-TAV peptide mixtures (single peptide specificity in three donors, adjacent self-antigen peptide specificity in one donor and nonspecific reactivity in one donor). None of them produced cytotoxic activity or responded to 2A-ERAV. These results suggest that exposure to viral-derived 2A sequences is unlikely to produce unwanted T cell responses in immunocompetent individuals and further supports their continued use for studies of human gene therapy.
journal_name
Gene Therjournal_title
Gene therapyauthors
Arber C,Abhyankar H,Heslop HE,Brenner MK,Liu H,Dotti G,Savoldo Bdoi
10.1038/gt.2013.25subject
Has Abstractpub_date
2013-09-01 00:00:00pages
958-62issue
9eissn
0969-7128issn
1476-5462pii
gt201325journal_volume
20pub_type
杂志文章相关文献
GENE THERAPY文献大全abstract::In high-risk patients, the ideal cardiovascular gene therapy requires a strategy that provides long-term protection of myocardium against episodes of ischemic/reperfusion injury. We report the development of an efficient, long-lasting pre-emptive gene therapy strategy in a rat model of ischemic-reperfusion (I/R) injur...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302250
更新日期:2004-06-01 00:00:00
abstract::The potential of gene therapy for treatment of lung disease remains unrealised. Early model systems often resulted in promising efficiency of gene transfer, only to prove irreproducible in the clinic. While problems such as induction of host immune responses and duration of expression also need to be addressed, it is ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301146
更新日期:2000-04-01 00:00:00
abstract::Studies reviewed show that lentiviral gene therapy directed either at inhibiting the synthesis of brain acetaldehyde generated from ethanol or at degrading brain acetaldehyde fully prevent ethanol intake by rats bred for their high alcohol preference. However, after animals have chronically consumed alcohol, the above...
journal_title:Gene therapy
pub_type: 杂志文章,评审
doi:10.1038/s41434-019-0064-9
更新日期:2019-11-01 00:00:00
abstract::The successful development of adenovirus vectors for vaccines and gene therapy will require a better understanding of the host immune response. Using the ELISPOT assay to measure IFN-gamma-secreting CD8(+) cells, we identify immunodominant epitopes of the adenovirus hexon and DNA-binding protein in BALB/c and C57BL/6 ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302232
更新日期:2004-05-01 00:00:00
abstract::Naturally occurring drug resistance genes of human origin can be exploited for selection of genetically engineered cells co-expressing a desired therapeutic transgene. Their non-immunogenicity in clinical applications would be a major asset. Human cytidine deaminase (hCD) is a chemoresistance gene that inactivates cyt...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301675
更新日期:2002-04-01 00:00:00
abstract::Bone marrow stromal cells (MSCs) are pluripotent cells capable of differentiation into several tissue types. This present study was performed to determine their functional neoangiogenic potential in vivo. Whole bone marrow was harvested from C57Bl/6 mice, and the adherent cellular fraction was culture expanded for 14 ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301934
更新日期:2003-04-01 00:00:00
abstract::Citrullinemia type 1 (CTLN1) is an autosomal recessive disorder of metabolism caused by a deficiency of argininosuccinate synthetase. Despite optimal management, CTLN1 patients still suffer from lethal metabolic instability and experience life-threatening episodes of acute hyperammonemia. A murine model of CTLN1 (fold...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2013.53
更新日期:2013-12-01 00:00:00
abstract::Integration site analysis was performed on six dogs with canine leukocyte adhesion deficiency (CLAD) that survived greater than 1 year after infusion of autologous CD34+ bone marrow cells transduced with a gammaretroviral vector expressing canine CD18. A total of 387 retroviral insertion sites (RIS) were identified in...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2008.52
更新日期:2008-07-01 00:00:00
abstract::Introducing exogenous genes into cells is one of the most important molecular techniques to study gene functions. Comparing to other type of cells, neurons are more difficult to transfect with cDNAs because they are very sensitive to microenvironmental changes. Among various gene transfer techniques, the Ca(2+)-phosph...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302305
更新日期:2004-09-01 00:00:00
abstract::Inadequate antiprotease activity in the lungs due to alpha-1-antitrypsin (A1AT) deficiency is a factor of early-onset emphysema. We propose a new approach to gene therapy that involves the intratracheal delivery of macrophages expressing human A1AT (hA1AT). Recombinant adeno-associated virus (rAAV) plasmids encoding t...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302121
更新日期:2003-12-01 00:00:00
abstract::Interferon-alpha (IFN-alpha) or CD80 transduction of tumor cells individually reduces tumorigenicity and enhances antitumor responses. Here, we report that the combination of IFN-alpha and CD80 cancer gene therapy in poorly immunogenic murine tumor models, the colorectal adenocarcinoma cell line MC38, and the methylch...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301034
更新日期:1999-12-01 00:00:00
abstract::Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are associated with diverse disorders and characterized by disruption of the alveolar-capillary barrier, leakage of edema fluid into the lung, and substantial inflammation leading to acute respiratory failure. Gene therapy is a potentially powerful...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2016.19
更新日期:2016-06-01 00:00:00
abstract::We report the discovery, on routine screening, of a replication-competent retrovirus (RCR) produced from a third generation amphotropic packaging cell line, GP + envAM12. In this line, the gag-pol and env helper genes are located on separate plasmids to minimise the chances of recombination events that may lead to RCR...
journal_title:Gene therapy
pub_type: 杂志文章
doi:
更新日期:1996-07-01 00:00:00
abstract::Hepatic fibrosis is a common outcome of chronic liver diseases. In schistosomiasis, chronic parasite egg-induced granuloma formation can lead to fibrosis, which is immunologically characterized by the dominant Th2 response. Recently, it has been shown that gene therapy is an attractive approach for the treatment of he...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301524
更新日期:2001-09-01 00:00:00
abstract::The CMV promoter drives high transgene expression and is one of the most commonly used promoters for gene transfer. Tissue-specific mammalian promoters provide an alternative, and it would be useful to have a system to directly compare them to viral promoters free from potential confounding vector-related effects. In ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302700
更新日期:2006-05-01 00:00:00
abstract::Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301328
更新日期:2000-12-01 00:00:00
abstract::Morphine appears to be the most active metabolite of heroin; therefore, the effects of morphine are important in understanding the ramifications of heroin abuse. Opioid physical dependence (withdrawal response) may have very long-lasting effects on the motivation for reward, including the incubation of cue-induced dru...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2017.22
更新日期:2017-05-01 00:00:00
abstract::In the last two decades, remarkable advances have been made in the development of technologies used to engineer new aptamers and ribozymes. This has encouraged interest among researchers who seek to create new types of gene-control systems that can be made to respond specifically to small-molecule signals. Validation ...
journal_title:Gene therapy
pub_type: 杂志文章,评审
doi:10.1038/gt.2009.81
更新日期:2009-10-01 00:00:00
abstract::The role of two receptors, previously proposed to mediate the entry of adenoviruses into human cells, the coxsackie and adenovirus receptor (CAR) and the major histocompatibility complex (MHC) class I heavy chain has been investigated. The expression of MHC class I in many tumours is reduced or absent, therefore if th...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301006
更新日期:1999-09-01 00:00:00
abstract::Catheter-based percutaneous transluminal gene delivery (PTGD) into the coronary artery still falls behind the expectations of an efficient myocardial gene delivery system. In this study gene delivery was applied by selective pressure-regulated retroinfusion through the coronary veins to prolong adhesion of replication...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301079
更新日期:2000-02-01 00:00:00
abstract::During the past decade, both in vitro and in vivo studies have provided new insights into the cellular and molecular mechanisms that govern angiogenesis and arteriogenesis. However, therapeutic angiogenesis clinical trials using recombinant protein or gene therapy formulations of single angiogenic growth factors have ...
journal_title:Gene therapy
pub_type: 杂志文章,评审
doi:10.1038/sj.gt.3302953
更新日期:2007-05-01 00:00:00
abstract::Retroviral vectors have become the primary tool for gene delivery into hematopoietic cells, including T lymphocytes. Lentiviral vectors offer an advantage over Moloney murine leukemia virus (MuLV) vectors because of their ability to translocate across an intact nuclear membrane and integrate into the genome of nonprol...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301378
更新日期:2001-02-01 00:00:00
abstract::Adoptive immunotherapy of cancer using chimeric antigen receptor (CAR)-engineered T cells with redirected specificity showed efficacy in recent trials. In preclinical models, 'second-generation' CARs with CD28 costimulatory domain in addition to CD3ζ performed superior in redirecting T-cell effector functions and surv...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2010.127
更新日期:2011-01-01 00:00:00
abstract::We previously demonstrated that recombinant adeno-associated virus vectors based on serotype 2 (rAAV2) can direct transgene expression in salivary gland cells in vitro and in vivo. However, it is not known how other rAAV serotypes perform when infused into salivary glands. The capsids of serotypes 4 and 5 are distinct...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302691
更新日期:2006-04-01 00:00:00
abstract::Cellular immunity against cancer can be achieved with viral vector- and DNA-based immunizations. In preclinical studies, cancer vaccines are very potent, but in clinical trials these potencies are not achieved yet. Thus, a rational approach to improve cancer vaccines is warranted. We previously demonstrated that the r...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2015.24
更新日期:2015-07-01 00:00:00
abstract::The pressing challenge for contemporary gene therapy is to deliver enough therapeutic genes to enough cancer cells in vivo. With the aim of improving viral distribution and tumor penetration, we explored the use of decorin to enhance viral spreading and tumor tissue penetration. We generated decorin-expressing replica...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2009.142
更新日期:2010-02-01 00:00:00
abstract::Conditionally replicating adenoviruses (CRAd) are a promising class of gene therapy agents that can overcome already known glioblastoma (GBM) resistance mechanisms but have limited distribution upon direct intratumoral (i.t.) injection. Collagen bundles in the extracellular matrix (ECM) have an important role in inhib...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2012.42
更新日期:2013-03-01 00:00:00
abstract::In order to characterize protein targeting signals in polarized postmitotic cortical neurones in vitro, we have developed recombinant and amplicon type vectors derived from herpes simplex virus 1 (HSV1) to transfer genes into these cells. We examined the targeting of both bacterial proteins, which lack specific target...
journal_title:Gene therapy
pub_type: 杂志文章
doi:
更新日期:1994-01-01 00:00:00
abstract::Radioiodide concentrating activity in the thyroid, mediated by human Na+/I- symporter (hNIS), provides a mechanism for effective radioiodide treatment for patients who have invasive, recurrent, and metastatic thyroid cancers after total thyroidectomy. In an attempt to develop hNIS gene transfer for radioiodide therapy...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301170
更新日期:2000-05-01 00:00:00
abstract::This report examines the commercialization of gene therapy in the context of innovation theories that posit a relationship between the maturation of a technology through its life cycle and prospects for successful product development. We show that the field of gene therapy has matured steadily since the 1980s, with th...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2013.72
更新日期:2014-02-01 00:00:00